Y-mAbs Therapeutics CFO Bo Kruse resigns; search for successor underway

Y-mAbs Therapeutics, Inc.

Bo Kruse informed Y-mAbs of his resignation as CFO, effective upon appointment of a successor and then as employee on July 31, 2024.
He will remain CFO until successor is identified and joins the company; then continue as non-executive employee through July 31.
Resignation is not due to any disagreement with the company's operations, policies, or practices.
Company has commenced a search process for a new CFO.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Bo Kruse

Chief Financial Officer

Y-mAbs Therapeutics, Inc.

Filed: March 14, 2024, 7:59 PM ET

On March 8, 2024, Bo Kruse, Executive Vice President, Chief Financial Officer, Secretary and Treasurer of Y-mAbs Therapeutics, Inc. (the “Company”), informed the Company of his intention to resign from such offices effective as of the date the Company appoints his successor and such successor commences employment with the Company (the “Successor Effective Date”) and to resign from employment with the Company effective July 31, 2024 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bo Kruse resigned as Chief Financial Officer at Y-mAbs Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On March 8, 2024, Bo Kruse, Executive Vice President, Chief Financial Officer, Secretary and Treasurer of Y-mAbs Therapeutics, Inc. (the “Company”), informed the Company of his intention to resign from such offices effective as of the date the Company appoints his successor and such successor commences employment with the Company (the “Successor Effective Date”) and to resign from employment with the Company effective July 31, 2024 (the “Effective Date”).

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-24-034340

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.